Atopic Dermatitis Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Therapy, and Region

Description

List of Tables

The atopic dermatitis market size is expected to reach USD 22.37 billion by 2034, according to a new study by Polaris Market Research. The report "Atopic Dermatitis Market Size, Share, Trends, Industry Analysis Report: By Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors, and Others), Route of Administration, Therapy, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Atopic dermatitis is a chronic inflammatory skin condition characterized by itching, redness, and skin barrier dysfunction, often associated with allergic diseases such as asthma and hay fever. The atopic dermatitis market growth is driven by increasing disease prevalence, rising awareness, and advancements in treatment options, including biologics and JAK inhibitors. The market benefits from ongoing research, regulatory approvals, and investments in innovative therapies that offer improved efficacy and safety.

Atopic dermatitis market opportunities exist in expanding access to treatments in emerging economies and leveraging digital health technologies for better disease management. Key trends include the adoption of personalized medicine, the rise of online pharmacy distribution, and strategic collaborations among pharmaceutical companies to strengthen product pipelines. These factors collectively contribute to the market expansion and evolving competitive landscape.

Atopic Dermatitis Market Report Highlights

The atopic dermatitis market, by drug class, is segmented into biologics, calcineurin inhibitors, corticosteroids, PDE4 inhibitors, and others. The biologics segment accounted for a major market share in 2024.
The market, by route of administration, is segmented into topical, injectable, and oral. The injectable segment dominated the atopic dermatitis market share in 2024. This dominance is largely attributed to the widespread adoption of injectable biologic therapies.
North America accounted for a major share of the atopic dermatitis market revenue in 2024 due to the high prevalence of atopic dermatitis and substantial healthcare expenditures.
The market comprises several key pharmaceutical companies actively involved in developing and marketing treatments for this chronic skin condition. A few notable participants are AbbVie Inc.; Allergan plc; Almirall, S.A.; Astellas Pharma Inc.; Bayer AG; Eli Lilly and Company; Galderma S.A.; Incyte Corporation; LEO Pharma A/S; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi S.A.

Polaris Market Research has segmented the atopic dermatitis market report on the basis of drug class, route of administration, therapy, and region:

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

Biologics
Calcineurin Inhibitors
Corticosteroids
PDE4 Inhibitors
Others

By Route of Administration Outlook (Revenue - USD Billion, 2020-2034)

Topical
Injectable
Oral

By Therapy Outlook (Revenue - USD Billion, 2020-2034)

Photo Therapy
Directed Therapy

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM1317

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. Global Atopic Dermatitis Market Insights

4.1. Atopic Dermatitis Market - Market Snapshot
4.2. Atopic Dermatitis Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.2. Restraints and Challenges
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Atopic Dermatitis Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Atopic Dermatitis Market, by Drug Class

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
5.3. Biologics
- 5.3.1. Global Atopic Dermatitis Market, by Biologics, by Region, 2020-2034 (USD Billion)
5.4. Calcineurin Inhibitors
- 5.4.1. Global Atopic Dermatitis Market, by Calcineurin Inhibitors, by Region, 2020-2034 (USD Billion)
5.5. Corticosteroids
- 5.5.1. Global Atopic Dermatitis Market, by Corticosteroids, by Region, 2020-2034 (USD Billion)
5.6. PDE4 Inhibitors
- 5.6.1. Global Atopic Dermatitis Market, by PDE4 Inhibitors, by Region, 2020-2034 (USD Billion)
5.7. Others
- 5.7.1. Global Atopic Dermatitis Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Atopic Dermatitis Market, by Route of Administration

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
6.3. Topical
- 6.3.1. Global Atopic Dermatitis Market, by Topical, by Region, 2020-2034 (USD Billion)
6.4. Injectable
- 6.4.1. Global Atopic Dermatitis Market, by Injectable, by Region, 2020-2034 (USD Billion)
6.5. Oral
- 6.5.1. Global Atopic Dermatitis Market, by Oral, by Region, 2020-2034 (USD Billion)

7. Global Atopic Dermatitis Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
7.3. Hospital Pharmacies
- 7.3.1. Global Atopic Dermatitis Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
7.4. Retail Pharmacies
- 7.4.1. Global Atopic Dermatitis Market, by Retail Pharmacies, by Region, 2020-2034 (USD Billion)
7.5. Online Pharmacies
- 7.5.1. Global Atopic Dermatitis Market, by Online Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Atopic Dermatitis Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Atopic Dermatitis Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. Atopic Dermatitis Market - North America
- 8.3.1. North America: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
- 8.3.2. North America: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.3.3. North America: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.4. Atopic Dermatitis Market - U.S.
  - 8.3.4.1. U.S.: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.5. Atopic Dermatitis Market - Canada
  - 8.3.5.1. Canada: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4. Atopic Dermatitis Market - Europe
- 8.4.1. Europe: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.2. Europe: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.4.3. Europe: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.4. Atopic Dermatitis Market - UK
  - 8.4.4.1. UK: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.4.2. UK: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.5. Atopic Dermatitis Market - France
  - 8.4.5.1. France: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.5.2. France: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.4.5.3. France: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.6. Atopic Dermatitis Market - Germany
  - 8.4.6.1. Germany: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.7. Atopic Dermatitis Market - Italy
  - 8.4.7.1. Italy: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.8. Atopic Dermatitis Market - Spain
  - 8.4.8.1. Spain: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.9. Atopic Dermatitis Market - Netherlands
  - 8.4.9.1. Netherlands: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.10. Atopic Dermatitis Market - Russia
  - 8.4.10.1. Russia: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.11. Atopic Dermatitis Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5. Atopic Dermatitis Market - Asia Pacific
- 8.5.1. Asia Pacific: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.4. Atopic Dermatitis Market - China
  - 8.5.4.1. China: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.4.2. China: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.5.4.3. China: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.5. Atopic Dermatitis Market - India
  - 8.5.5.1. India: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.5.2. India: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.5.5.3. India: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.6. Atopic Dermatitis Market - Malaysia
  - 8.5.6.1. Malaysia: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.7. Atopic Dermatitis Market - Japan
  - 8.5.7.1. Japan: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.8. Atopic Dermatitis Market - Indonesia
  - 8.5.8.1. Indonesia: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.9. Atopic Dermatitis Market - South Korea
  - 8.5.9.1. South Korea: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.10. Atopic Dermatitis Market - Australia
  - 8.5.10.1. Australia: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.11. Atopic Dermatitis Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6. Atopic Dermatitis Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.4. Atopic Dermatitis Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.5. Atopic Dermatitis Market - UAE
  - 8.6.5.1. UAE: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.6. Atopic Dermatitis Market - Israel
  - 8.6.6.1. Israel: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.7. Atopic Dermatitis Market - South Africa
  - 8.6.7.1. South Africa: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.8. Atopic Dermatitis Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
8.7. Atopic Dermatitis Market - Latin America
- 8.7.1. Latin America: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.4. Atopic Dermatitis Market - Mexico
  - 8.7.4.1. Mexico: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.5. Atopic Dermatitis Market - Brazil
  - 8.7.5.1. Brazil: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.6. Atopic Dermatitis Market - Argentina
  - 8.7.6.1. Argentina: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.7. Atopic Dermatitis Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Atopic Dermatitis Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America: Atopic Dermatitis Market, by Route of Administration, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: Atopic Dermatitis Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Pfizer Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Sanofi S.A.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. AbbVie Inc.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Galderma S.A.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Eli Lilly and Company
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Regeneron Pharmaceuticals, Inc.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. LEO Pharma A/S
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Otsuka Pharmaceutical Co., Ltd.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Novartis AG
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Incyte Corporation
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development